Effect of the addition of protease inhibitors to sputa from cystic fibrosis patients.
Costello
C M
CM
Department of Medicine, University College Dublin.
McQuaid
K
K
O'Connor
C M
CM
Fitzgerald
M X
MX
D015119:Aminocaproic Acid / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000201:enzymology*; D004492:Edetic Acid / Q000494:pharmacology; D005033:Ethylmaleimide / Q000494:pharmacology; D006801:Humans; D007531:Isoflurophate / Q000494:pharmacology; D019272:Leukocyte Elastase; D010196:Pancreatic Elastase / Q000032:analysis; D010618:Phenanthrolines / Q000494:pharmacology; D010664:Phenylmethylsulfonyl Fluoride / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology*; D013048:Specimen Handling / Q000379:methods; D013183:Sputum / Q000187:drug effects / Q000201:enzymology; D000515:alpha 1-Antitrypsin / Q000032:analysis
D010618:Phenanthrolines; D011480:Protease Inhibitors; D000515:alpha 1-Antitrypsin; D007531:Isoflurophate; D010664:Phenylmethylsulfonyl Fluoride; D004492:Edetic Acid; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase; D005033:Ethylmaleimide; D015119:Aminocaproic Acid; C025205:1,10-phenanthroline